Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a late-stage biopharmaceutical company focused on central nervous system (CNS), inflammatory, and cardiometabolic diseases. The RVPH news feed highlights the company’s progress in advancing its pipeline, particularly its lead candidate brilaroxazine (RP5063), which is being developed for schizophrenia and explored for additional indications such as pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF).
News updates commonly cover clinical trial milestones, including data from the Phase 3 RECOVER program in schizophrenia and its 1-year open-label extension. Reviva has reported broad-spectrum efficacy across major symptom domains, reductions in proinflammatory cytokines, and long-term safety and tolerability data for brilaroxazine. The company also releases information on biomarker research, such as vocal biomarker analyses that use speech latency to characterize negative symptoms and enrich antipsychotic clinical trials.
Regulatory and corporate developments are another key theme in RVPH news. Investors can follow announcements related to FDA interactions, including pre-New Drug Application (pre-NDA) feedback recommending a second Phase 3 trial in schizophrenia, as well as plans for the RECOVER-2 registrational study, subject to financing. Updates on Orphan Drug Designation for PAH and IPF, European patent grants for pulmonary fibrosis, and broader intellectual property strategy are also featured.
In addition, the news flow includes participation in scientific meetings, investor conferences, and key opinion leader events, where Reviva presents clinical and mechanistic data on brilaroxazine. For market participants tracking RVPH stock, this page consolidates company-issued press releases on clinical data, regulatory guidance, financing transactions, and strategic presentations in one place.
Summary not available.
Summary not available.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) will host a webinar on May 2, 2023, at 11:00 AM ET featuring KOL Larry Ereshefsky, PharmD, discussing brilaroxazine (RP5063), a serotonin-dopamine modulator in late development for schizophrenia. The event will cover the unmet medical need in schizophrenia treatment and Reviva's clinical trial data, including the ongoing RECOVER Phase 3 trial. Brilaroxazine has exhibited significant efficacy in a Phase 2 study, demonstrating improvements in PANSS total scores and meeting safety endpoints. Furthermore, it has potential for use in other neuropsychiatric and pulmonary conditions, having received Orphan Drug Designation from the FDA for certain indications. This webinar aims to provide insights on the treatment landscape and sustainable advancements in psychiatric and inflammatory therapies.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will present a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry from April 27-29, 2023, in San Diego, CA. The presentation, titled "Brilaroxazine (RP5063), a novel serotonin-dopamine stabilizer, displays antipsychotic efficacy in rodents," will take place on April 29, 2023, from 5:00-7:00 PM PT.
Brilaroxazine is a drug candidate showing significant clinical promise for treating schizophrenia and related disorders. In Phase 2 studies, it met primary endpoints, demonstrating efficacy with no adverse effects on weight or metabolic parameters. Additionally, it has potential applications in pulmonary diseases like PAH and IPF, having received Orphan Drug Designation from the FDA. Reviva aims to pursue further development of brilaroxazine for various neuropsychiatric conditions.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) will feature on The RedChip Money Report® on Bloomberg TV on April 22, 2023, at 7 p.m. ET. The interview includes insights from CEO Laxminarayan Bhat regarding the Company’s Phase 3 trial for schizophrenia and promising safety and efficacy results from the Phase 2 study. Reviva’s focus is on developing next-generation therapeutics to address unmet medical needs, with ongoing research on drug candidates like brilaroxazine (RP5063) and RP1208. Reviva holds composition of matter patents for both candidates in the U.S. and Europe. The RedChip Money Report® aims to provide investors with valuable information on small-cap investing and features various financial insights.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) reported financial results for the year ended December 31, 2022, highlighting significant progress towards brilaroxazine's NDA submission for treating schizophrenia. The pivotal Phase 3 RECOVER trial has enrolled over 50% of its 400 patients, with topline data expected mid-2023. The company reported a net loss of approximately $24.3 million, or $1.25 per share, compared to a loss of $8.5 million, or $0.58 per share in 2021. Cash and equivalents stood at $18.5 million as of December 31, 2022, sufficient to support operations through Q3 2023.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its CEO Laxminarayan Bhat will present at the 35th Annual Roth Conference from March 12-14, 2023, in Dana Point, California. The presentation will take place on March 13 at 3:00 p.m. PT. Reviva focuses on developing therapies for unmet medical needs, particularly in central nervous system, cardiovascular, metabolic, and inflammatory diseases. Their pipeline includes drug candidates brilaroxazine (RP5063) and RP1208. For more details, visit the webcast link.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a clinical-stage pharmaceutical company, will have its Founder and CEO, Laxminarayan Bhat, present at the BIO CEO and Investor Conference from February 6–9, 2023 in New York. The presentation is scheduled for February 6 at 11:30 p.m. EST. Reviva focuses on developing therapies for unmet medical needs in central nervous system, cardiovascular, metabolic, and inflammatory diseases. Their pipeline includes drug candidates RP5063 (brilaroxazine) and RP1208, both with composition of matter patents in multiple regions.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced progress in its Phase 3 RECOVER trial for brilaroxazine, targeting schizophrenia, with top-line data expected in mid-2023. Approximately 40% of patients have been treated with no serious adverse events reported. The company secured $8.5 million in funding to support this trial. Additionally, they completed a drug-drug interaction study showing brilaroxazine's favorable safety profile. Reviva aims to explore other indications, representing a combined market opportunity exceeding $70 billion. Upcoming milestones include potential NDA submission in 2025.
Reviva Pharmaceuticals Holdings announces positive results from a clinical drug-drug interaction study for brilaroxazine, a serotonin/dopamine modulator, essential for schizophrenia treatment. The study reinforces brilaroxazine's safety profile, showing no significant adverse interactions with CYP3A4 enzyme inhibitors. Topline data from the pivotal Phase 3 RECOVER trial is expected mid-2023, involving 400 patients over a 28-day regimen. The FDA may consider a 'Superior Safety' label for brilaroxazine based on positive Phase 3 results.